IXC Financial Statements | Balance Sheet, Income & Cash Flow Analysis
The financial statements for IXC (IXC) provide a snapshot of revenue trends, balance-sheet strength, and cash flow quality. Reviewing these together helps investors evaluate earnings durability, capital structure, and whether operating cash flow supports long-term business growth.
See stock fair value and complete historical financials—premium unlocks deeper tables and metrics.
Financial Statements
Related peers
Compare More →| PAR Paradigm Biopharmaceuticals Limited | $0.21 -2.27% |
| ZLD Zelira Therapeutics Limited | $0.50 +0.00% |
| CYP Cynata Therapeutics Limited | $0.32 +4.92% |
| VBS Vectus Biosystems Limited | $0.15 +0.00% |
| ACW Actinogen Medical Limited | $0.04 +2.63% |
| ATH Alterity Therapeutics Limited | $0.01 +0.00% |
| Peer | Price | Change | Market Cap | PE | EPS | Div Yield (TTM) | Analyst Rating | Volume |
|---|---|---|---|---|---|---|---|---|
| PAR Paradigm Biopharmaceuticals Limited | $0.21 | -2.27% | 97.13 M | -2.15 | -0.10 | 0.00% | Buy | 1.53 |
| ZLD Zelira Therapeutics Limited | $0.50 | +0.00% | 5.95 M | -1.56 | -0.32 | 0.00% | Hold | 19 |
| CYP Cynata Therapeutics Limited | $0.32 | +4.92% | 75.99 M | -8.00 | -0.04 | 0.00% | Buy | 211 |
| VBS Vectus Biosystems Limited | $0.15 | +0.00% | 8.01 M | -5.00 | -0.03 | 0.00% | — | 8 |
| ACW Actinogen Medical Limited | $0.04 | +2.63% | 140.07 M | -3.90 | -0.01 | 0.00% | Buy | 3.52 |
| ATH Alterity Therapeutics Limited | $0.01 | +0.00% | 97.88 M | -0.90 | -0.01 | 0.00% | Buy | 388 |
Frequently Asked Questions
What are IXC's latest financial results?
Review IXC's latest balance sheet, income statement, and cash flow to understand its profitability, revenue trends, and financial health. These metrics are essential for evaluating short-term performance and long-term stability.
How has IXC's revenue and net income changed over time?
Analyzing historical revenue and net income shows growth trends and business performance. Consistent growth indicates operational strength, while declines may signal challenges that investors should consider.
What is IXC's cash flow situation and liquidity?
Cash flow statements reveal how IXC generates and uses cash. Strong operating cash flow and sufficient liquidity suggest the company can fund operations, pay dividends, and handle debt effectively.
How does IXC's financial performance compare to industry peers?
Comparing key metrics like revenue growth, profit margins, and debt levels with competitors helps investors assess whether IXC is outperforming or lagging within its sector.
Are IXC's financial statements showing sustainable profitability?
By analyzing margins, ROE, ROIC, and cash generation over multiple periods, investors can evaluate whether IXC's profits are repeatable and supported by strong fundamentals.